Published in J Autoimmun on December 09, 2009
Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study | NCT00445913
Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol (2010) 2.26
Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity (2012) 0.98
The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes. J Autoimmun (2015) 0.91
Dendritic cell subsets in type 1 diabetes: friend or foe? Front Immunol (2013) 0.88
The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases. Front Immunol (2015) 0.85
CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L. J Leukoc Biol (2013) 0.84
Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment. J Leukoc Biol (2016) 0.78
FMS-like tyrosine kinase 3 ligand treatment does not ameliorate experimental rapidly progressive glomerulonephritis. PLoS One (2015) 0.75
FLT3 Ligand regulates thymic precursor cells and hematopoietic stem cells through interactions with CXCR4 and the marrow niche. Exp Hematol (2017) 0.75
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A (2007) 6.44
Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet (2001) 6.14
Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med (1996) 5.32
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med (2003) 3.74
Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med (1999) 3.45
Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med (2009) 3.13
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity (2005) 3.07
The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J Exp Med (2003) 2.65
Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell (1993) 2.40
Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature (2000) 2.39
Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest (2003) 2.37
Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes (2007) 2.27
Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes (1994) 2.16
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol (2009) 2.10
The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment. Diabetes (2008) 2.04
Hematologic effects of flt3 ligand in vivo in mice. Blood (1996) 2.02
Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol (2004) 1.86
Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med (1995) 1.67
Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol (1993) 1.65
Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest (1992) 1.64
Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation (2007) 1.56
Developmental control of CD8 T cell-avidity maturation in autoimmune diabetes. J Clin Invest (2005) 1.42
Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. Diabetes (2003) 1.30
Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose. Diabetes (1984) 1.26
Qualitative and quantitative abnormalities in splenic dendritic cell populations in NOD mice. Clin Exp Immunol (2004) 1.18
Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol (2004) 1.16
Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development. Int Immunol (2005) 1.15
Deficiency in NOD antigen-presenting cell function may be responsible for suboptimal CD4+CD25+ T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes (2006) 1.14
The good turned ugly: immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice. Immunol Rev (2005) 1.13
Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet (1995) 1.13
Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function. Clin Immunol (2009) 1.11
Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes (2006) 1.10
Increased generation of dendritic cells from myeloid progenitors in autoimmune-prone nonobese diabetic mice. J Immunol (2002) 1.07
Decreased blood dendritic cell counts in type 1 diabetic children. Clin Immunol (2007) 1.06
Flt3-ligand treatment prevents diabetes in NOD mice. Diabetes (2004) 1.06
Increased incidence of diabetes mellitus in specific pathogen-eliminated offspring produced by embryo transfer in NOD mice with low incidence of the disease. Lab Anim Sci (1994) 1.02
Cell-intrinsic effects of non-MHC NOD genes on dendritic cell generation in vivo. Int Immunol (2002) 1.01
Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: studies using NOD/CIITA-deficient mice. J Immunol (1999) 0.99
Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood. Clin Immunol (2008) 0.98
Requirement for both H-2Db and H-2Kd for the induction of diabetes by the promiscuous CD8+ T cell clonotype AI4. J Immunol (2004) 0.96
First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes. Diabetologia (2002) 0.95
Altered dendritic cells (DC) might be responsible for regulatory T cell imbalance and autoimmunity in nonobese diabetic (NOD) mice. Eur Cytokine Netw (2002) 0.92
Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models. Diabetes (2008) 0.90
Islet cell antibodies as predictive markers for IDDM in children with high background incidence of disease. Diabetes (1990) 0.89
Concise review: Dendritic cell development in the context of the spleen microenvironment. Stem Cells (2007) 0.79
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med (2006) 4.97
Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev (2011) 4.15
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med (2012) 2.86
CD8alphaalpha-mediated survival and differentiation of CD8 memory T cell precursors. Science (2004) 2.54
Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol (2008) 2.25
T-bet controls autoaggressive CD8 lymphocyte responses in type 1 diabetes. J Exp Med (2004) 1.88
Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev (2006) 1.81
Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest (2004) 1.73
A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Invest (2004) 1.51
Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J Clin Invest (2004) 1.49
CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity (2002) 1.48
Transgenic animal models for type 1 diabetes: linking a tetracycline-inducible promoter with a virus-inducible mouse model. Transgenic Res (2002) 1.43
Retracted Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies. Clin Dev Immunol (2006) 1.39
Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. J Clin Invest (2009) 1.37
Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol (2005) 1.34
Viral trigger for type 1 diabetes: pros and cons. Diabetes (2008) 1.33
Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes (2008) 1.25
Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity. J Virol (2006) 1.25
Real-time imaging of the pancreas during development of diabetes. Immunol Rev (2008) 1.13
Initiation of autoimmunity. Curr Opin Immunol (2004) 1.11
Novel strategies to eliminate persistent viral infections. Trends Immunol (2008) 1.11
Histopathology of type 1 diabetes: old paradigms and new insights. Rev Diabet Stud (2009) 1.09
OX40 facilitates control of a persistent virus infection. PLoS Pathog (2012) 1.05
Infections and autoimmunity--good or bad? J Immunol (2005) 1.05
IP-10 and type 1 diabetes: a question of time and location. Autoimmunity (2004) 1.00
Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity (2012) 0.98
Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? J Autoimmun (2009) 0.98
Following the fate of one insulin-reactive CD4 T cell: conversion into Teffs and Tregs in the periphery controls diabetes in NOD mice. Diabetes (2012) 0.96
Trials in type 1 diabetes: Antigen-specific therapies. Clin Immunol (2013) 0.95
The role of the activating receptor NKG2D in autoimmunity. Mol Immunol (2009) 0.94
Induction, acceleration or prevention of autoimmunity by molecular mimicry. Mol Immunol (2004) 0.93
Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimmun (2011) 0.92
Increased memory conversion of naïve CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure. PLoS One (2011) 0.91
Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies. Am J Pathol (2007) 0.91
Viral infections and molecular mimicry in type 1 diabetes. APMIS (2012) 0.90
The role of innate immunity in autoimmunity. J Exp Med (2004) 0.89
Islet beta-cell death - fuel to sustain autoimmunity? Immunity (2007) 0.89
Essential role for TLR9 in prime but not prime-boost plasmid DNA vaccination to activate dendritic cells and protect from lethal viral infection. J Immunol (2010) 0.89
Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood (2005) 0.89
TLR2 signaling improves immunoregulation to prevent type 1 diabetes. Eur J Immunol (2011) 0.89
Infection as a cause of type 1 diabetes? Curr Opin Rheumatol (2012) 0.88
Potential viral pathogenic mechanism in human type 1 diabetes. Diabetologia (2014) 0.88
Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice. Diabetes (2007) 0.87
NKG2D blockade facilitates diabetes prevention by antigen-specific Tregs in a virus-induced model of diabetes. J Autoimmun (2012) 0.87
Adenovirus E3 MHC inhibitory genes but not TNF/Fas apoptotic inhibitory genes expressed in beta cells prevent autoimmune diabetes. Proc Natl Acad Sci U S A (2009) 0.86
Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model. Diabetes (2013) 0.86
No significant CTL cross-priming by dendritic cell-derived exosomes during murine lymphocytic choriomeningitis virus infection. J Immunol (2009) 0.86
Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies. Clin Dev Immunol (2006) 0.85
Persistent glucose transporter expression on pancreatic beta cells from longstanding type 1 diabetic individuals. Diabetes Metab Res Rev (2011) 0.85
Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesis. J Autoimmun (2010) 0.84
Viruses and cytotoxic T lymphocytes in type 1 diabetes. Clin Rev Allergy Immunol (2011) 0.84
SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J Autoimmun (2006) 0.84
Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J Immunol (2002) 0.81
Manipulating the type 1 vs type 2 balance in type 1 diabetes. Immunol Res (2004) 0.80
Virally induced inflammation triggers fratricide of Fas-ligand-expressing beta-cells. Diabetes (2004) 0.80
Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology. Semin Immunopathol (2010) 0.80
Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced model. J Immunol (2011) 0.80
Cure of chronic viral infection by neutralizing antibody treatment. Autoimmun Rev (2006) 0.80
CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetes. J Autoimmun (2009) 0.80
Motifs for a deadly encounter. Nat Immunol (2012) 0.79
Regulatory T-cells in type 1 diabetes. Diabetes Metab Res Rev (2004) 0.79
Do viral infections protect from or enhance type 1 diabetes and how can we tell the difference? Cell Mol Immunol (2011) 0.79
Control of graft-versus-host disease by regulatory T cells: which level of antigen specificity? Eur J Immunol (2006) 0.78
Blockade but not overexpression of the junctional adhesion molecule C influences virus-induced type 1 diabetes in mice. PLoS One (2013) 0.78
Immunosuppressive mechanisms during viral infectious diseases. Methods Mol Biol (2011) 0.78
Cytokines and chemokines in virus-induced autoimmunity. Adv Exp Med Biol (2003) 0.77
Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells. Int J Radiat Biol (2014) 0.76
Virally induced inflammation and therapeutic avenues in type 1 diabetes. Endocrinol Metab Clin North Am (2004) 0.76
Minimal effect of CD103 expression on the control of a chronic antiviral immune response. Viral Immunol (2010) 0.76
Clinical potential of antigen-specific therapies in type 1 diabetes. Rev Diabet Stud (2012) 0.76
Erratum. Increased Immune Cell Infiltration of the Exocrine Pancreas: A Possible Contribution to the Pathogenesis of Type 1 Diabetes. Diabetes 2014;63:3880-3890. Diabetes (2016) 0.76
Combination therapy with InsB9-23 peptide immunization and CTLA4-IgG does not reverse diabetes in NOD mice. Clin Immunol (2011) 0.75
Interfacing dendritic and natural killer cells: a tool for targeted tolerance induction? Transplantation (2003) 0.75
Autoantibodies exacerbate the severity of MHV-induced encephalitis. Adv Exp Med Biol (2006) 0.75
Combination therapy with anti-CD6 and oral insulin immunization reverses recent onset diabetes in non obese diabetic mice but fails to induce lasting tolerance. Clin Immunol (2013) 0.75